Recruiting
Phase 1
Phase 2

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT06596694

Conditions

Gastrointestinal Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Patritumab deruxtecan

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information